Synonyms: Compound A [WO2022119905A2]
Compound class:
Synthetic organic
Comment: Uplarafenib is the INN for a BRAF inhibitor that was designed as an antineoplastic agent. It is one of the compounds claimed in patent WO2022119905A2 (NeuPharma) [1]. Uplarafenib is likely Henlius/NeuPharma lead BRAF asset HLX208 (RX208), that is designed to target oncogenic BRAFV600E.
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
IUPAC Name ![]() |
N-[2,4,5-trifluoro-3-(3-morpholin-4-ylquinoxaline-6-carbonyl)phenyl]propane-1-sulfonamide |
Synonyms ![]() |
Compound A [WO2022119905A2] |
Database Links ![]() |
|
CAS Registry No. | 1425485-87-5 (source: WHO INN record) |
GtoPdb PubChem SID | 485206003 |
PubChem CID | 71506198 |
Search Google for chemical match using the InChIKey | HAYBWDINAFTFCJ-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | HAYBWDINAFTFCJ |
UniChem Compound Search for chemical match using the InChIKey | HAYBWDINAFTFCJ-UHFFFAOYSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | HAYBWDINAFTFCJ-UHFFFAOYSA-N |
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.
✖
Uplarafenib (links to external site)
Cat. No. HY-148059 |